The number of CD3−CD56+ NK cells decreased in glioma patients, and these NK cells highly expressed TIM3, an immune checkpoint related to glioma progression (Han et al., 2014), leading to a decreased capability of IFN-γ secretion. Here, IFNG is linked to central nervous system cancer.